Tag Archives: transparency

DIY healthcare tops PwC’s HRI 10 issues for 2015

PwC’s Health Research Institute (HRI) announced its top 10 health industry issues for 2015. The HRI’s top three emphasizes the possibilities of mobile device technologies for do-it-yourself (DIY) healthcare and the potential privacy concerns that could arise.
Posted in Strategy | Also tagged , , | Leave a comment

The Year of Living Openly: Europe and Transparency 2015

The past year has brought significant changes not only in regulatory mandates and guidances but also regarding a broader overall emphasis on coordination of information and processes. The regulators have prioritized transparency and harmonization for some time but underscored them to an even greater degree in 2014; 2015 is likely to see the trend intensify.
Posted in compliance, Europe, Global, Guest Blog | Also tagged , , , , , | Leave a comment

EMA Revises Conflict-of-Interest Policy

The European Medicines Agency (EMA) has published its revised policy on handling declarations of interests for scientific-committee members and experts. The revisions strive for a more balanced approach in restricting the involvement of experts with possible conflicts of interests in the Agency’s work, while maintaining access to expertise.
Posted in compliance, Europe, Regulatory | Also tagged , , , | Leave a comment

More Finger Pointing Over Sunshine System Snafus

Further delays in implementing the Open Payments program for disclosing industry financial relationships with prescribers has ignited a blame-game over who is at fault. The Centers for Medicare and Medicaid Services (CMS) is citing inaccurate data from pharma and medical device companies for the latest problems involving erroneous payment attributions. Manufacturers maintain they fully validate […]
Posted in Op-Ed, Regulatory | Also tagged , , , | Leave a comment

Open Payments: A New Dawn for Transparency

The Physicians Payment Sunshine Act, more formally referred to as Open Payments, has been in place for almost 18 months. It is only in the next few months, however, that the implications of the law and its contentious requirements will start to be fully realised. Michael Christel reports.
Posted in compliance, Events, FDA, Meetings, Regulatory | Also tagged , , , , | Leave a comment
  • Categories

  • Meta